The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict ViroPharma's revenues will wither -19.8% and EPS will wither -20.0%.
The average estimate for revenue is $109.0 million. On the bottom line, the average EPS estimate is $0.20.
Last quarter, ViroPharma logged revenue of $106.5 million. GAAP reported sales were 27% lower than the prior-year quarter's $145.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.10. GAAP EPS were -$0.09 for Q4 versus $0.65 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 71.6%, much worse than the prior-year quarter. Operating margin was -4.2%, much worse than the prior-year quarter. Net margin was -5.3%, much worse than the prior-year quarter.
The full year's average estimate for revenue is $463.1 million. The average EPS estimate is $0.82.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,200 members out of 1,239 rating the stock outperform, and 39 members rating it underperform. Among 314 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 308 give ViroPharma a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ViroPharma is outperform, with an average price target of $32.81.
- Add ViroPharma to My Watchlist.